Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers

Clinical Biochemistry

Volumn 40, Issue 16-17, 2007, Pages 1180-1187

  Bogavac Stanojević, Nataša ^a   Ivanova Petrova, Guenka ^b   Jelić Ivanović, Zorana ^a   Memon, Lidija ^c   Spasić, Slavica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c Clinical Centre Beanijska kosa   (Serbia)

Author keywords

Apolipoproteins; Coronary artery disease; Cost effectiveness; hs CRP; Lipids; Lipoproteins

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; LIPOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; FRAMINGHAM SCORE; HEALTH CARE COST; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; APOLIPOPROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 35248865222     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.07.004     Document Type: Article

References (30)

1. Kaplan W, Laing R. Priority medicines for Europe and the world. WHO, Geneva 2004. WHO/EDM/PAR/2004.7.
2. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, opportunities. N. Engl. J. Med. 337 (1997) 1360-1369
3. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
4. Carmena R., Duriez P., and Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 109 Suppl. III (2004) III2-III7
5. Fuster V. Conner memorial lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90 (1994) 2126-2146
6. Conroy R.M., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24 (2003) 987-1003
7. Gordon D.J., and Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N. Engl. J. Med. 321 (1989) 1311-1316
8. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
9. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur. Heart J. 24 (2003) 1601-1610
10. Genest Jr. J., McNamara J.R., Ordovas J.M., et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J. Am. Coll. Cardiol. 19 (1992) 792-802
11. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 104 (2001) 1108-1113
12. Walldius G., and Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur. Heart J. 26 (2005) 210-212
13. Schaefer E.J., Lamon-Fava S., Jenner J.L., et al. Lipoprotein (a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271 (1994) 999-1003
14. Wild S.H., Fortmann S.P., and Marcovina S.M. A prospective case-control study of lipoprotein (a) levels and apo (a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 239-245
15. Ridker P.M., Hennekens C.H., and Stampfer M.J. A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 270 (1993) 2195-2199
16. Cantin B., Gagnon F., Moorjani S., et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular study. J. Am. Coll. Cardiol. 31 (1998) 519-525
17. Yang Q., Khoury M.J., Botto L., Friedman J.M., and Flanders W.D. Improving the prediction of complex disease by testing for multiple disease-susceptibility genes. Am. J. Hum. Genet. 72 (2003) 636-649
18. Meisinger C., Loewel H., Mraz W., and Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur. Heart J. 26 (2005) 271-278
19. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004) 1387-1397
20. Rifai N., and Ridker P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 47 (2001) 403-411
21. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
22. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centres for disease control and prevention and the American Heart Association. Circulation 107 (2003) 499-511
23. http://www.jr2.ox.ac.uk/bandolier/band27/b27-2.html.
24. Elliot R., and Payne K. Essential of Economic Evaluation in Healthcare (2005), Pharmaceutical Press, London 104-110
25. Takemura Y., Ishida H., Inoue Y., and Beck J.R. Yield and costs of individual common diagnostic tests in new primary care outpatients in Japan. Clin. Chem. 48 (2002) 42-54
26. Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat. Med. 17 (1998) 873-890
27. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
28. Berg K., Dahlen G., Christophersen B., Cook T., Kjekshous J., and Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet. 52 (1997) 254-261
29. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347 (2002) 1557-1565
30. Ridker P.M. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am. J. Cardiol. 92 (2003) 7K-22K (suppl)